Time to dial back on diabetes treatment in older patients? Study finds 11 percent are overtreated

September 15, 2017

Anyone with diabetes who takes blood sugar medication knows their doctor prescribed it to help them. After all, the long-term effects of elevated blood sugar can harm everything from the heart and kidneys to the eyes and feet.

But what if stopping, or at least cutting back on, such drugs could help even more in some patients?

In some older people, such "deintensification" of diabetes treatment may be the safer route, because of the risks of falls and other issues that come with too-low blood sugar.

But a new study in the Journal of General Internal Medicine suggests more doctors and such patients should work together to dial back diabetes treatment.

Who's over-treated?

Almost 11 percent of Medicare participants with diabetes had very low blood sugar levels that suggested they were being over-treated, the new study finds. But only 14 percent of these patients had a reduction in blood sugar medication refills in the next six months.

Patients over age 75, and those who qualified for both Medicare and Medicaid because of low incomes or serious disability, were most likely to be over-treated. Those who lived in urban areas or were of Hispanic origin were less likely to be over-treated.

Patients over age 75 were less likely than others to have their treatment dialed back, as measured by prescription doses and refills.

But patients who had more than six chronic conditions, or who lived in urban areas or had frequent outpatient visits, were more likely to experience a deintensification.

The results were compiled by a team of researchers from Duke University, the University of Michigan and the VA hospitals in Durham, North Carolina and Ann Arbor, Michigan. They studied detailed records from 78,792 Medicare participants over age 65 in ten states, all of whom had diabetes.

The authors, led by Duke/Durham researcher Matthew Maciejewski, Ph.D., warn against a one-size-fits-all approach when treating diabetes in older patients. They call for greater personalized care that takes account of the risks and benefits that such treatment holds for individual patients.

Jeremy Sussman, M.D., M.S., a co-author of the new study and U-M/VA researcher, suggests that older patients with diabetes - and the adult children who often assist with their care - should talk to their care teams about whether de-intensification is right for them.

The risk of too-aggressive treatment

In people in their 70s and older, very low blood sugar levels - called hypoglycemia -- can actually raise the risk of dizzy spells, confusion, falls and even death.

In recent years, experts have started to suggest that doctors ease up on how aggressively they treat such patients for high blood pressure or diabetes -- especially if they have other conditions that limit their life expectancy.

It can be hard for an older person to recognize the signs of too-low blood sugar, such as confusion and combativeness, or of too-low blood pressure, such as dizziness.

Meanwhile, keeping up with taking multiple medications, and checking blood sugar daily or even more often, can be a struggle for the oldest patients. De-intensifying their treatment can often be a relief.

A previous study by Sussman and his U-M/VA colleagues showed that only one in four of nearly 400,000 older patients in the VA system who could have been eligible to ease up on their blood sugar medicines actually had their dosage changed.

Even those with the lowest readings, or the fewest years left to live, had only a slightly greater chance as other patients of having their treatment de-intensified.

The VA system is actively trying to encourage de-intensification of blood sugar-reducing treatment in its oldest patients nationwide. The U-M/Ann Arbor VA team, led by Eve Kerr, M.D., M.S., is studying the effects of that effort.

More about the new study

For the new study, the team looked at prescription refills among those whose blood sugar levels - represented by a measure called HbA1c - were already well below recommended levels.

They focused on those who had an A1c at or below 6.5 percent, at a single point in time in 2011 - as well as those with an A1c over 9, which is considered very high.

The patients under 6.5 A1c levels would be eligible to ease up on their blood sugar medication dosages, to lower their risk of the consequences of hypoglycemia.

In fact, the American Geriatrics Society recommends that the only medication an older person with diabetes should be on if they have an A1c level below 7.5 percent is metformin.

While 10.9 percent of all the Medicare participants in the study were being over-treated to the point of an ultra-low A1c level, only 6.9 percent were being under-treated and had A1c levels over 9.

"The oldest Medicare beneficiaries are the least likely to benefit from tight glycemic control and most likely to be harmed, so it is troubling that they were more likely to be overtreated and less likely to have their medication regimens de-intensified," explains Sussman, who is a member of the VA Center for Clinical Management Research and the U-M Institute for Healthcare Policy and Innovation.

"By focusing on both overtreatment and undertreatment ends of the diabetes quality spectrum, we can best begin to improve the quality of diabetes care in all respects, ensuring that patients get needed care while avoiding unnecessary potential harm," he adds.

Long-term gain, short-term pain

Sussman notes that the reasons why doctors prescribe medication to help people get their diabetes under control mostly focus on the long term.

Controlling these factors for years can help people cut their risk of problems that result from too-high sugar levels, like stroke, heart attack, blindness, nerve damage, amputation and kidney failure.

"Every guideline for physicians has detailed guidance for prescribing and stepping up or adding drugs to control these risk factors, and somewhere toward the end it says 'personalize treatment for older people'," says Sussman, a U-M assistant professor of general internal medicine and VA Ann Arbor researcher. "But nowhere do they say actually stop medication in the oldest patients to avoid hypoglycemia or too-low blood pressure."

If a patient has been on medication for diabetes for many years, and is now in their late 70s or older, they may have gotten many long-term benefits from keeping their levels in control.

But because their chance of a dangerous blood sugar or blood pressure dip goes up with age, the short-term risk starts to balance out any long-term gain they could still get.

Sussman and his colleagues write that effective treatment of diabetes requires a major shift in approach towards greater personalization of treatments based on potential for individual risk and benefit.
-end-


Michigan Medicine - University of Michigan

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.